The program for phenotyping of genetically modified animals at AstraZeneca.
Genetically modified mice offer a wide range of possibilities in preclinical drug discovery, e.g. for use in target identification, target validation and disease model generation. However, genomic modification and alteration in gene expression may cause unpredicted phenotypic alterations in the organism other than the intended ones. The aim of this study was to determine the importance of establishing the phenotype of transgenic and knockout mice models for use in pharmaceutical research. A total number of 51 mouse models (transgenic and knockout) produced at AstraZeneca during a 4 year period were subjected to a thorough phenotyping package covering clinical as well as morphological aspects. Phenotype abnormalities were recorded in 36 (70.6%) of the mouse models. The majority of findings were considered to be minor in magnitude. Histopathological changes related to the genotype of the animals were observed in 33% of the mouse models, underlining the importance of pathology in the phenotyping program.
Berg
Anna-Lena
AL
Safety Assessment, AstraZeneca R&D Södertälje, S-151 85 Södertälje, Sweden. Anna-Lena.Berg@astrazeneca.com
Bohlooly-Y
Mohammad
M
D000818:Animals; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D016130:Immunophenotyping; D051379:Mice; D018345:Mice, Knockout / Q000235:genetics*; D008822:Mice, Transgenic / Q000235:genetics*; D023421:Models, Animal; D010641:Phenotype